Table 3.
Characteristic | All patients (n = 83) | |
---|---|---|
Age, median (years) | 74.0 (45–85) | |
Sex | Female | 13 (15.7%) |
Male | 70 (84.3%) | |
Smoking status | Never | 1 (1.2%) |
Former | 39 (47.0%) | |
Current | 43 (51.8%) | |
Brinkman index, median (pack-year) | 56.0 (0–162) | |
Cell differentiation | Well/Moderately/Poorly | 18 (21.7%) |
Moderately | 54 (65.1%) | |
Poorly | 11 (13.3%) | |
Pathologic stage | IA | 41 (49.4%) |
(IA1/IA2/IA3) | (1/15/25) | |
IB | 42 (50.6%) | |
Mode of lung resection | Sub-lobar resection | 18 (21.7%) |
Lobectomy | 65 (78.3%) | |
Adjuvant chemotherapy | Performed | 11(13.3%) |
(UFT/Platimun-based) | (4/7) | |
NLR, median (range) | 2.2 (0.9–7.5) | |
PD-L1 expression (TPS) | 0 | 40 (48.2%) |
≥1% | 43 (51.8%) | |
≥5% | 31 (37.3%) | |
≥10% | 25 (30.1%) | |
≥50% | 14 (16.9%) |
Data represented as absolute counts (%) or median (range).
NLR, neutrophil-to-lymphocyte ratio.
TPS, tumor proportion score.
UFT, tegafur and uracil.